Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Vitiligo, an acquired depigmenting disorder of the skin that reacts against normal melanocytes, sometimes occurs as an immune-related adverse event in the treatment of melanoma with immune checkpoint inhibitors. It has been known that the occurrence of vitiligo is associated with a favorable therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Furune, Satoshi, Kondo, Chiaki, Takano, Yuko, Shimokata, Tomoya, Sugishita, Mihoko, Mitsuma, Ayako, Maeda, Osamu, Ando, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787012/
https://www.ncbi.nlm.nih.gov/pubmed/35116218
http://dx.doi.org/10.1007/s13691-021-00515-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787012/
https://www.ncbi.nlm.nih.gov/pubmed/35116218
http://dx.doi.org/10.1007/s13691-021-00515-w

Ejemplares similares